Navigation Links
New target discovered to treat epileptic seizures following brain trauma or stroke

New therapies for some forms of epilepsy may soon be possible, thanks to a discovery made by a team of University of British Columbia and Vancouver Coastal Health Research Institute neuroscience researchers.

The researchers found that hemichannels - the same channels the researchers previously found to that cause cell death following a stroke - may also cause epileptic seizures that occur following head trauma or a stroke.

The findings, published tomorrow in Science, will allow researchers to focus on new treatments that block these channels. A hemichannel is a channel that can form in nerve cells which allows chemical ions to pass through.

"The glutamate receptor that is linked to cell death following a stroke also triggers opening of hemichannels," says UBC Psychiatry Prof. Brian MacVicar, who is a member of the Brain Research Centre at UBC and VCH Research Institute. "Therefore both stroke itself or the glutamate released by a stroke can open hemichannels and cause cell death or epileptic seizures."

The researchers tested the effect of glutamate at levels less than those reached during stroke and found that more moderate activation of glutamate receptors opens hemichannels and causes seizure but does not produce cell death associated with stroke.

Glutamate is one of the brain's most abundant chemical messengers. Gap junctions are connections that allow molecules and ions, to flow between cells. Junctions are composed of two hemichannels that bridge intercellular space.

When epileptic seizures occur, hemichannels unexpectedly open near the synapses, which disrupt the normal electrical activity of the brain leading to seizures.

"We found that blocking hemichannels reduced the epilepsy-like discharges," says Roger Thompson, a former UBC Psychiatry post-doctoral Fellow who is now an Assistant Professor of Cell Biology, Anatomy and Clinical Neurosciences at the University of Calgary.

"With these results we are confident that the discovery of safe blockers of hemichannels will provide a new therapy in the treatment to reduce cell loss and seizures that are caused by stroke," says MacVicar, who also holds the Canada Research Chair in Neuroscience at UBC.

"The next step will be to develop a compound to block brain cell hemichannels from opening," says MacVicar. "Therapies for epilepsy patients who have suffered a stroke or head trauma may be available within five to 10 years."

According to the BC Epilepsy Society it is estimated that one out of 12 people will have a seizure in their lifetime, and close to one in 100 Canadians have epilepsy. An epileptic seizure is an abnormal burst of electrical activity within the brain.


Contact: Catherine Loiacono
University of British Columbia

Related medicine news :

1. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
2. NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals
3. WHO tool helps target bone treatment
4. Broccoli compound targets key enzyme in late-stage cancer
5. New breast imaging technology targets hard-to-detect cancers
6. IDO2 an active enzyme to target in pancreatic cancer
7. Experts: Targeted agricultural investments will yield high results, slash poverty in Africa
8. Combining targeted therapy drugs may treat previously resistant tumors
9. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
10. UCSD researchers identify potential new drug target for chronic leukemia
11. TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade
Post Your Comments:
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced that Dr. Christine Milligan, Global ... Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy ... , FDA has long asserted that design and manufacture of Laboratory Developed ... and do not meet the device regulations. , Come up short in an inspection ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Bolier Reactor System. Brillouin is the developer of renewable energy technologies capable of ... nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015   HeartWare International, Inc ... less-invasive, miniaturized circulatory support technologies that are revolutionizing the ... and Chief Executive Officer Doug Godshall is ... Annual Healthcare Conference on December 1, 2015 at ... 1-2 in New York . ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... iRhythm Technologies, Inc. , a leading digital health care solutions ... participate in the 27th Annual Piper Jaffray Healthcare Conference at The ... . Kevin King , Chief Executive Officer of iRhythm, ... ET. --> --> About ... . --> iRhythm is a privately held digital ...
Breaking Medicine Technology: